Hillevax Inc (HLVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hillevax Inc (HLVX) has a cash flow conversion efficiency ratio of -0.005x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-789.00K) by net assets ($147.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HLVX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Hillevax Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Hillevax Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hillevax Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hillevax Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Feng Ching Metal
TWO:2061
|
-0.030x |
|
Bonus Biogroup
TA:BONS
|
0.710x |
|
Carnaby Resources Ltd
AU:CNB
|
-0.074x |
|
AVer Information Inc
TW:3669
|
0.019x |
|
Horizon Minerals Ltd
AU:HRZ
|
-0.107x |
|
Fidelix Co. Ltd
KQ:032580
|
-0.050x |
|
Singha Estate Public Company Limited
BK:S
|
0.022x |
|
MegaStudy Co. Ltd
KQ:072870
|
0.031x |
Annual Cash Flow Conversion Efficiency for Hillevax Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Hillevax Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Hillevax Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $154.49 Million | $-108.79 Million | -0.704x | -115.46% |
| 2023-12-31 | $265.52 Million | $-86.78 Million | -0.327x | -40.90% |
| 2022-12-31 | $267.23 Million | $-61.99 Million | -0.232x | -420.39% |
| 2021-12-31 | $-100.76 Million | $-7.29 Million | 0.072x | -84.22% |
| 2020-12-31 | $-2.77 Million | $-1.27 Million | 0.459x | -35.06% |
| 2019-12-31 | $-671.00K | $-474.00K | 0.706x | -- |
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more